Skip to content

Severe asthma and biologics

TL;DR — Severe asthma is asthma requiring high-dose ICS plus a second controller and/or systemic corticosteroid to prevent loss of control, or remaining uncontrolled despite that treatment, after diagnosis and contributory factors are addressed (Chung 2014, PMID 24337046). The work-up before biologics—objective confirmation, inhaler technique, adherence, exposure and comorbidity—is part of treatment because “difficult-to-treat” disease is not automatically pharmacologically severe. Licensed biologics reduce annual exacerbations overall by 44% (rate ratio 0.56, 95% CI 0.51–0.62) and hospitalizations by 60% (0.40, 0.27–0.60), but average FEV1 improvement is about 0.11 L and symptom/quality-of-life gains often fall below their individual minimal important differences (Kyriakopoulos 2024, PMID 38657997). Blood eosinophils, FeNO, allergy and comorbid nasal polyps modify response probability; none guarantees response. The principal therapeutic goals are fewer attacks, withdrawal of maintenance oral corticosteroids, better function and demonstrable value at reassessment—not indefinite continuation by default.

Severe versus difficult-to-treat asthma

Category Operational meaning Correct response
Uncontrolled asthma Frequent symptoms and/or attacks, persistent limitation or high-risk treatment exposure Identify why control is poor
Difficult-to-treat asthma Uncontrolled despite medium/high-intensity treatment, often because of diagnosis, delivery, adherence, exposure or comorbidity Structured optimization
Severe asthma Requires high-dose ICS plus another controller/systemic steroid to remain controlled, or remains uncontrolled despite optimized therapy Phenotype and consider add-on targeted therapy (Chung 2014, PMID 24337046)

Severity cannot be assigned from a prescription list without knowing whether medication is used and delivered. Conversely, proving nonadherence does not imply mild disease; both can coexist.

Pre-biologic assessment

Domain Minimum assessment Why it changes the decision
Diagnosis Spirometry/variability or challenge; review onset and mimics Avoids biologic treatment for inducible laryngeal obstruction, COPD, bronchiectasis or cardiac disease
Treatment delivery Device-specific observed technique; refill/dose data Apparent high-dose exposure may be nominal only
Adherence Nonjudgmental interview, dispensing data, FeNO suppression where appropriate Correctable underexposure can mimic steroid-refractory inflammation
Exposure Smoke/vape, allergens, occupation, drugs Removal may outperform pharmacologic escalation
Comorbidity Rhinosinusitis/polyps, obesity, sleep apnea, reflux when symptomatic, anxiety/dysfunctional breathing Can drive symptoms or favor a biologic serving two diseases
Attack phenotype Dates, systemic-steroid courses, ED/hospital/ICU events Establishes baseline risk and future response denominator
Type-2 markers Repeated blood eosinophils, FeNO, IgE/sensitization; consider sputum Steroids suppress markers; historical maxima can be informative
Steroid toxicity Bone, metabolic, eye, adrenal, infection and cardiovascular burden Makes steroid withdrawal a co-primary target (Bleecker 2020, PMID 31525297)

This sequence is not bureaucracy. Starting an expensive targeted drug without a verified baseline makes both nonresponse and success hard to interpret.

Class-level effect and its limits

A meta-analysis of 48 RCTs and 16,350 participants found licensed biologics associated with:

Outcome Pooled effect
Annual exacerbations Rate ratio 0.56 (95% CI 0.51–0.62)
Hospitalizations Rate ratio 0.40 (0.27–0.60)
Prebronchodilator FEV1 Mean +0.11 L (0.09–0.14)
ACQ Mean −0.34 points (−0.46 to −0.23)
AQLQ Mean +0.38 points (0.26–0.49)

Effects were generally larger with type-2 inflammation, and agents/classes were heterogeneous (Kyriakopoulos 2024, PMID 38657997). The pooled ACQ and AQLQ changes are below conventional 0.5-point minimal important differences, while attack reductions are substantial. This is why response should not be judged from symptoms alone.

Anti-IgE: omalizumab

Omalizumab binds free IgE and reduces FcεRI-mediated allergic effector activation. Eligibility generally requires convincing allergic asthma plus total IgE/body-weight dosing within a jurisdiction-specific table.

INNOVATE randomized 419 people with severe persistent allergic asthma. Adjusted clinically significant exacerbation rates were 0.68 with omalizumab versus 0.91 with placebo, a 26% reduction; severe-exacerbation rates were 0.24 versus 0.48 and emergency-visit rates 0.24 versus 0.43 over 28 weeks (Humbert 2005, PMID 15679715).

Total IgE should not be used as a serial response marker because omalizumab changes measured circulating IgE complexes. Response is clinical: attacks, steroid exposure, control and function.

Practical cautions include injection reactions and rare anaphylaxis; observation and self-administration rules differ by setting.

Anti-IL-5 and anti-IL-5R

Mepolizumab

DREAM enrolled 621 patients with recurrent attacks and eosinophilic inflammation. Exacerbation rates were 2.40/year with placebo versus 1.24, 1.46 and 1.15 across three IV mepolizumab doses—reductions of 48%, 39% and 52%, without a simple dose-response relationship (Pavord 2012, PMID 22901886).

MENSA randomized 576 patients. IV and subcutaneous mepolizumab reduced exacerbations by 47% and 53%; ED/hospital events fell 32% and 61%, while placebo-adjusted FEV1 gains were about 0.10 L (Ortega 2014, PMID 25199059).

In SIRIUS, 135 oral-steroid-dependent patients had a median 50% maintenance-dose reduction with mepolizumab versus 0% with placebo; odds of moving to a lower dose stratum were 2.39 (95% CI 1.25–4.56) while exacerbations also fell 32% (Bel 2014, PMID 25199060).

Benralizumab

Benralizumab targets IL-5Rα and depletes eosinophils through antibody-dependent cellular cytotoxicity. SIROCCO enrolled 1,205 patients with severe uncontrolled asthma and stratified by blood eosinophils at 300 cells/μL; exacerbation reductions were greatest in the eosinophil-high population (Bleecker 2016, PMID 27609408).

ZONDA randomized 220 maintenance-steroid-dependent patients. Median oral-glucocorticoid reduction was 75% with either benralizumab schedule versus 25% with placebo; exacerbations fell 55% with four-week and 70% with eight-week dosing, while FEV1 did not significantly differ (Nair 2017, PMID 28530840).

Reslizumab

Weight-based IV reslizumab phase 3 trials enrolled patients with eosinophils at least 400 cells/μL and prior attacks; the duplicated trials reduced exacerbations compared with placebo (Castro 2015, PMID 25736990).

Formulation matters. Fixed-dose 110 mg subcutaneous reslizumab failed its overall exacerbation endpoint (RR 0.79, 95% CI 0.56–1.12) and steroid-sparing endpoint (OR 1.23, 0.70–2.16); higher drug exposure and eosinophils ≥400 cells/μL were associated with better results (Bernstein 2020, PMID 32066536). Evidence for one route/dose should not be generalized to another.

Anti-IL-4Rα: dupilumab

Dupilumab blocks IL-4 and IL-13 signaling through IL-4Rα. It is especially relevant when high FeNO, eosinophilia, atopic dermatitis or nasal polyps coexist.

QUEST randomized 1,902 people. Dupilumab 200 mg every two weeks reduced annual severe exacerbations from 0.87 to 0.46 (47.7%) and improved FEV1 by 0.14 L over placebo; with eosinophils ≥300 cells/μL, exacerbations fell 65.8% (Castro 2018, PMID 29782217).

VENTURE randomized 210 oral-steroid-dependent patients. Mean steroid reduction was 70.1% with dupilumab versus 41.9% with placebo; 48% versus 25% discontinued oral steroid, despite a 59% lower severe-exacerbation rate and 0.22 L higher FEV1 (Rabe 2018, PMID 29782224).

Transient blood eosinophilia occurred more often with dupilumab—4.1% versus 0.6% in QUEST—and rare clinically important eosinophilic complications require context-sensitive evaluation (Castro 2018, PMID 29782217).

Anti-TSLP: tezepelumab

Tezepelumab blocks epithelial TSLP, an upstream alarmin. NAVIGATOR randomized 1,061 adolescents/adults:

Outcome Tezepelumab Placebo Effect
Annual exacerbation rate, overall 0.93 2.10 RR 0.44 (95% CI 0.37–0.53)
Annual rate, eosinophils <300/μL 1.02 1.73 RR 0.59 (0.46–0.75)
Week-52 FEV1 change +0.23 L +0.09 L Difference +0.13 L (0.08–0.18)
ACQ-6 change −1.55 −1.22 Difference −0.33 (−0.46 to −0.20)

(Menzies-Gow 2021, PMID 33979488)

Benefit at eosinophils below 300 cells/μL broadens eligibility, but subgroup effects remain larger as type-2 markers rise. “Broad” does not mean biomarker-independent.

SOURCE did not meet its overall oral-steroid-sparing primary endpoint, an important negative result when choosing a biologic primarily to withdraw maintenance steroids (Phinyo 2024, PMID 37972921).

DESTINATION extended randomized safety/efficacy assessment to 104 weeks and supported persistence of attack reduction without a new dominant safety signal (Menzies-Gow 2023, PMID 36702146).

Choosing when eligibility overlaps

Feature Favors consideration Does not prove
Clear perennial allergic asthma within dosing table Omalizumab That IgE is the only active pathway
Repeated eosinophilia and attacks Anti-IL-5/5R, dupilumab or tezepelumab Head-to-head superiority
High FeNO Dupilumab or tezepelumab response probability That eosinophils are irrelevant
Maintenance oral steroid Mepolizumab, benralizumab or dupilumab have positive steroid-sparing RCTs Equal efficacy in every phenotype (Phinyo 2024, PMID 37972921)
Nasal polyps/atopic dermatitis Choose an agent with evidence/authorization for both diseases That comorbidity response guarantees asthma response
Low current type-2 markers Tezepelumab may remain eligible That suppressed historical eosinophilia should be ignored
Dosing/route preference Can determine real adherence Biological superiority

A live PubMed and ClinicalTrials.gov re-query on 2026-08-30 found that direct head-to-head asthma RCT evidence remains limited. Indirect comparisons are vulnerable to different entry criteria, placebo attack rates, biomarker thresholds and steroid-taper protocols.

A target-trial emulation of 201 overlapping-eligible patients reported 0.46, 0.93 and 1.32 exacerbations/person-year for dupilumab, omalizumab and mepolizumab; adjusted dupilumab-versus-mepolizumab IRR was 0.28 (95% CI 0.09–0.84), but small numbers and residual confounding prevent a universal ranking (Akenroye 2023, PMID 36740144).

Oral-corticosteroid stewardship

Repeated bursts and maintenance treatment produce cumulative metabolic, bone, infection, eye, adrenal and cardiovascular harm. A 139-study systematic review found risk rising with cumulative systemic-steroid exposure, including repeated short courses (Bleecker 2020, PMID 31525297).

For steroid-dependent asthma, a network meta-analysis of seven RCTs and 1,052 patients found steroid-reduction ORs versus placebo of 4.12 (2.22–7.64) for benralizumab every eight weeks, 4.09 (2.22–7.55) every four weeks, 3.25 (1.90–5.55) for dupilumab and 2.39 (1.25–4.57) for mepolizumab. Tralokinumab, tezepelumab and fixed-dose subcutaneous reslizumab were ineffective in their included trials (Phinyo 2024, PMID 37972921).

Steroid taper must consider adrenal suppression. Biologic response does not make abrupt withdrawal safe.

Assessing response

Record the baseline period and reassess after an agent-appropriate interval.

Domain Useful response metric
Attacks Annualized systemic-steroid, ED, hospital and ICU events
Steroid burden Maintenance dose, cumulative bursts and discontinuation
Control ACQ/ACT plus nocturnal symptoms, activity and reliever use
Physiology FEV1, reversibility and, where relevant, mucus/air trapping research endpoints
Biomarkers Direction consistent with mechanism, interpreted with treatment exposure
Comorbidity Nasal-polyp, dermatitis or urticaria outcomes where relevant
Burden Injection burden, adverse effects, access, cost and patient priorities

Define nonresponse before starting. If response is partial, recheck adherence, exposure and whether the wrong outcome was expected; then consider switching rather than layering biologics outside evidence.

Real-world evidence and switching

Real-world meta-analysis found large pre/post reductions in attacks with anti-IL-5/5R agents, but most studies were retrospective and unadjusted, so regression to the mean and treatment-selection bias inflate effect estimates (Charles 2022, PMID 35174566).

Switching is common when response is inadequate or comorbidity priorities change. The evidence is mainly observational; washout, outcome definitions and reasons for switching vary (Scioscia 2023, PMID 37298514).

Combination biologic therapy lacks adequate efficacy, safety and cost evidence for routine asthma use.

Long-term safety and stopping

Open-label extensions provide exposure data but lose placebo comparison. COLUMBA followed 347 mepolizumab-treated patients for a mean 3.5 years (1,201 patient-years); serious adverse events occurred in 23%, six deaths were judged unrelated, and clinical benefit persisted in continuing participants (Khatri 2019, PMID 30359681).

TRAVERSE enrolled 2,282 prior dupilumab-trial participants for up to 96 additional weeks; safety remained consistent with the established profile, with nasopharyngitis and injection-site erythema common (Wechsler 2022, PMID 34597534).

Optimal duration is unknown. A live ClinicalTrials.gov re-query on 2026-08-30 identified a not-yet-recruiting phase 4 study of dupilumab withdrawal in severe asthma (estimated n=205), with strategy failure over 24 months as its primary outcome ([NCT06818019](https://clinicaltrials.gov/study/NCT06818019){target="_blank" rel="noopener"}). This corrects the stale implication that no stopping trial exists; no result is yet available, and stopping studies must distinguish relapse of active biology from withdrawal of a symptomatic effect and specify rescue rules.

Remission

Clinical remission on treatment usually requires no attacks, no maintenance systemic steroid, controlled symptoms and stable/improved lung function for a specified period. Definitions differ and do not establish immunologic cure (Menzies-Gow 2020, PMID 31866436).

Remission should raise the bar for success while preserving honest language: “on-treatment clinical remission” is not eradication of susceptibility.

Open questions

  • Which prospective head-to-head algorithm best chooses among overlapping biologics?
  • Can maintenance oral corticosteroids be eliminated without adrenal or attack harm in every responder? (Phinyo 2024, PMID 37972921)
  • What defines adequate response, partial response and failure across attack, steroid and patient-reported domains?
  • When can a biologic be stopped after on-treatment remission, and what predicts durable off-treatment control? A prospective dupilumab-withdrawal study is registered but has not started recruitment as of 2026-08-30 (Menzies-Gow 2023, PMID 36702146; NCT06818019).
  • Which therapy changes airway remodeling rather than only attacks and biomarkers?
  • How should access and opportunity cost be incorporated into biologic selection across health systems?

References

  1. Chung KF, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343-373. PMID 24337046
  2. Kyriakopoulos C, et al. Biologic agents licensed for severe asthma: systematic review and meta-analysis of RCTs. Eur Respir Rev. 2024. PMID 38657997
  3. Bleecker ER, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020. PMID 31525297
  4. Humbert M, et al. Omalizumab add-on therapy in severe allergic asthma: INNOVATE. Allergy. 2005;60:309-316. PMID 15679715
  5. Pavord ID, et al. Mepolizumab for severe eosinophilic asthma: DREAM. Lancet. 2012;380:651-659. PMID 22901886
  6. Ortega HG, et al. Mepolizumab treatment in severe eosinophilic asthma: MENSA. N Engl J Med. 2014;371:1198-1207. PMID 25199059
  7. Bel EH, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma: SIRIUS. N Engl J Med. 2014;371:1189-1197. PMID 25199060
  8. Bleecker ER, et al. Benralizumab in severe asthma: SIROCCO. Lancet. 2016;388:2115-2127. PMID 27609408
  9. Nair P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma: ZONDA. N Engl J Med. 2017;376:2448-2458. PMID 28530840
  10. Castro M, et al. Reslizumab for inadequately controlled asthma with elevated eosinophils: two phase 3 trials. Lancet Respir Med. 2015;3:355-366. PMID 25736990
  11. Bernstein JA, et al. Fixed-dose subcutaneous reslizumab in severe uncontrolled and steroid-dependent asthma. Lancet Respir Med. 2020. PMID 32066536
  12. Castro M, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma: QUEST. N Engl J Med. 2018;378:2486-2496. PMID 29782217
  13. Rabe KF, et al. Dupilumab in glucocorticoid-dependent severe asthma: VENTURE. N Engl J Med. 2018;378:2475-2485. PMID 29782224
  14. Menzies-Gow A, et al. Tezepelumab in severe uncontrolled asthma: NAVIGATOR. N Engl J Med. 2021;384:1800-1809. PMID 33979488
  15. Phinyo P, et al. Biologics for oral-corticosteroid-dependent asthma: systematic review and network meta-analysis. J Allergy Clin Immunol Pract. 2024. PMID 37972921
  16. Menzies-Gow A, et al. Long-term safety and efficacy of tezepelumab: DESTINATION. Lancet Respir Med. 2023. PMID 36702146
  17. Akenroye AT, et al. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab: target trial emulation. J Allergy Clin Immunol. 2023. PMID 36740144
  18. Charles D, et al. Real-world efficacy of benralizumab, dupilumab, mepolizumab and reslizumab: systematic review and meta-analysis. Clin Exp Allergy. 2022. PMID 35174566
  19. Scioscia G, et al. Switching biological therapies in severe asthma. J Asthma Allergy. 2023. PMID 37298514
  20. Khatri S, et al. Long-term safety and durability of mepolizumab in severe eosinophilic asthma: COLUMBA. J Allergy Clin Immunol. 2019. PMID 30359681
  21. Wechsler ME, et al. Long-term safety and efficacy of dupilumab: TRAVERSE. Lancet Respir Med. 2022. PMID 34597534
  22. Menzies-Gow A, et al. Expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020. PMID 31866436
  23. Pilette C, et al. REALITI-A: real-world oral corticosteroid-sparing effect of mepolizumab. J Allergy Clin Immunol Pract. 2022. PMID 35753668
  24. Agache I, et al. EAACI systematic review of biologicals for severe eosinophilic asthma. Allergy. 2020. PMID 32034960
  25. Busse W, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol. 2019. PMID 30205189
  26. Corren J, et al. Baseline type 2 biomarkers and response to tezepelumab in severe asthma. Allergy. 2022. PMID 34913186
  27. Bacharier LB, et al. Dupilumab in children with uncontrolled moderate-to-severe asthma. N Engl J Med. 2021;385:2230-2240. PMID 34879449
  28. Shackleford S, et al. Clinical remission with biologics: systematic review and meta-analysis. Eur Respir Rev. 2025. PMID 39549709
  29. ClinicalTrials.gov API v2. Dupilumab withdrawal in severe asthma; record re-fetched 2026-08-30. NCT06818019.